Author:
Kahn Rebecca,Zielinski Lindsay,Gedlinske Amber,Askelson Natoshia M.,Petersen Christine,Parker Andrew M.,Gidengil Courtney A.,Albert Alison P.,Jiles Angela J.,Lindley Megan C.,Kobayashi Miwako,Scherer Aaron M.
Publisher
Centers for Disease Control MMWR Office
Subject
Health Information Management,Health, Toxicology and Mutagenesis,General Medicine,Health (social science),Epidemiology
Reference10 articles.
1. Kobayashi M. Considerations for age-based and risk-based use of PCV15 and PCV20 among U.S. adults and proposed policy options. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; October 20, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/02-Pneumococcal-Kobayashi-508.pdf
2. Older adults hospitalized for pneumonia in the United States: incidence, epidemiology, and outcomes.;Arnold;J Am Geriatr Soc,2020
3. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices—United States, 2022.;Kobayashi;MMWR Morb Mortal Wkly Rep,2022
4. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).;Tomczyk;MMWR Morb Mortal Wkly Rep,2014
5. Physician survey regarding updated PCV13 vaccine recommendations for adults ≥65 years.;Hurley;J Am Geriatr Soc,2021
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献